Neurobiology of Schizophrenia Spectrum Disorders: The Role of Oxidative Stress

被引:0
作者
Wood, Stephen J. [1 ]
Yuecel, Murat [2 ]
Pantelis, Christos
Berk, Michael [2 ,3 ,4 ,5 ]
机构
[1] Univ Melbourne & Melbourne Hlth, Natl Neurosci Facil, Melbourne Neuropsychiat Ctr, Dept Psychiat, Carlton, Vic 3053, Australia
[2] Univ Melbourne, ORYGEN Res Ctr, Melbourne, Vic, Australia
[3] Barwon Hlth, Dept Clin & Biomed Sci, Geelong, Vic, Australia
[4] Univ Melbourne, Geelong Clin, Geelong, Vic, Australia
[5] Mental Hlth Res Inst, Melbourne, Vic, Australia
关键词
Glutathione; Magnetic resonance spectroscopy; N-acetyl cysteine; N-ACETYL-CYSTEINE; ETHYL-EICOSAPENTAENOIC ACID; POLYUNSATURATED FATTY-ACIDS; PLACEBO-CONTROLLED TRIAL; GLUTATHIONE-PEROXIDASE; 1ST-EPISODE PSYCHOSIS; PSYCHIATRIC-DISORDERS; CEREBROSPINAL-FLUID; LIPID-PEROXIDATION; THERAPEUTIC IMPLICATIONS;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mitochondrial dysfunction and oxidative stress are increasingly implicated in the pathophysiology of schizophrenia. The brain is the body's highest energy consumer, and the glutathione system is the brain's dominant free radical scavenger. In the current paper, we review the evidence of central and peripheral nervous system anomalies in the oxidative defences of individuals with schizophrenia, principally involving the glutathione system. This is reflected by evidence of the manifold consequences of oxidative stress that include lipid peroxidation, protein carboxylation, DNA damage and apoptosis - all potentially part of the process of neuroprogression in the disorder. Importantly, oxidative stress is amenable to intervention. We consider the clinical potential of some possible interventions that help reduce oxidative stress, via augmentation of the glutathione system, particularly N-acetyl cysteine. We argue that a better understanding of the mechanisms and pathways underlying oxidative stress will assist in developing the therapeutic potential of this area.
引用
收藏
页码:396 / 401
页数:6
相关论文
共 69 条
[1]  
ABDALLA DSP, 1986, CLIN CHEM, V32, P805
[2]   The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients The possible role of oxidant/antioxidant imbalance [J].
Akyol, Ö ;
Herken, H ;
Uz, E ;
Fadillioglu, E ;
Ünal, S ;
Sögüt, S ;
Özyurt, H ;
Savas, HA .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2002, 26 (05) :995-1005
[3]   Erythrocyte superoxide dismutase and glutathione peroxidase activities, and malondialdehyde and reduced glutathione levels in schizophrenic patients [J].
Altuntas, I ;
Aksoy, H ;
Coskun, I ;
Çayköylü, A ;
Akçay, F .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2000, 38 (12) :1277-1281
[4]  
ANDERSSON RGG, 1977, ACTA PHARMACOL TOX, V41, P1
[5]   Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients [J].
Arvindakshan, M ;
Sitasawad, S ;
Debsikdar, V ;
Ghate, M ;
Evans, D ;
Horrobin, DF ;
Bennett, C ;
Ranjekar, PK ;
Mahadik, SP .
BIOLOGICAL PSYCHIATRY, 2003, 53 (01) :56-64
[6]   Oxidative stress reduces renal dopamine D1 receptor-Gq/11α G protein-phospholipase C signaling involving G protein-coupled receptor kinase 2 [J].
Banday, Anees Ahmad ;
Lokhandwala, Mustafa F. .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2007, 293 (01) :F306-F315
[7]   Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study [J].
Berger, Gregor E. ;
Wood, Stephen J. ;
Wellard, R. Mark ;
Proffitt, Tina M. ;
McConchie, Mirabel ;
Amminger, G. Paul ;
Jackson, Graeme D. ;
Velakoulis, Dennis ;
Pantelis, Christos ;
McGorry, Patrick D. .
NEUROPSYCHOPHARMACOLOGY, 2008, 33 (10) :2467-2473
[8]   Ethyl-eicosapentaenoic acid in first-episode psychosis: A randomized, placebo-controlled trial [J].
Berger, Gregor E. ;
Proffitt, Tina-Marie ;
McConchie, Mirabel ;
Yuen, HokPan ;
Wood, Stephen J. ;
Amminger, G. Paul ;
Brewer, Warrick ;
McGorry, Patrick D. .
JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (12) :1867-1875
[9]   Supersensitive platelet glutamate receptors as a possible peripheral marker in schizophrenia [J].
Berk, M ;
Plein, H ;
Csizmadia, T .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1999, 14 (02) :119-122
[10]  
Berk M, 2000, LIFE SCI, V66, P2427, DOI 10.1016/S0024-3205(00)00573-7